iiinova — where your digital self keeps evolving

Reposted by Anna Minchom

Dr Colin Lindsay @drcolinlindsay.bsky.social · 27/03/2025

1) KRYSTAL-7 update on pembro+adagrasib in 1st line pdl1 >50% nsclc. Tox to navigate but mPFS >27m! Further reinforcing the view that ras orchestrates TME, not just cancer cell intrinsic pathways. Massive congrats to investigators, mirati, bms #ELCC25

065

Reposted by Anna Minchom

Dr Colin Lindsay @drcolinlindsay.bsky.social · 27/03/2025

2) daraxonrasib (rmc-6236) offering early phase and v impressive activity in g12d g12v 2nd line nsclc. RR 38% and mPFS >10m. V tolerable toxicity profile again. Next will be IO combos, congrats+++ to Revolution Medicines and the investigators. #ELCC25

043

Reposted by Anna Minchom

Jo Evans. @oncolojo.bsky.social · 05/03/2025

@annaminchom.bsky.social on newer small cell therapeutic strategies and management of CRS and ICANS as specific TRAEs With thought around timings of dose delivery and education of AOS teams and patients, safely deliverable within the NHS #BTOG25

187

Reposted by Anna Minchom

Sanjay Popat @drsanjaypopat.bsky.social · 05/03/2025

Agree. A packed room for SCLC on the last day of a conference? Unheard of previously! Obviously all attending to listen to @annaminchom.bsky.social , @drjnaidoo.bsky.social ,& @stephenvliu.bsky.social! @btog.bsky.social #BTOG25

0135

Reposted by Anna Minchom

Tom Newsom-Davis @tnewsomdavis.bsky.social · 04/03/2025

Matt Krebs on NHS England ctDNA pilot To make ctDNA cost effective, tissue NGS testing in some patients needs to be stopped How do we (safely) do this? ❇️ Actionable Tier 1 mutation present ➡️ no tissue NGS confirmation needed ❇️ Non-informative ctDNA: still need tissue NGS ❗️Guidelines coming ❗️

096

Reposted by Anna Minchom

Tom Newsom-Davis @tnewsomdavis.bsky.social · 03/03/2025

Poster session absolutely packed: Loud, energetic, crowded Brilliant ❤️

022

Reposted by Anna Minchom

Ben Bellenie @chemb.bsky.social · 03/03/2025

A great talk Adam, really enjoyed hearing about the breadth of your work!

132

Reposted by Anna Minchom

BTOG @btog.bsky.social · 03/03/2025

The Welcome and Updates session will be chaired by @DrSanjayPopat, with Neal Navani, Rolf Stahel and Thierry Berghmans speaking. #BTOG25

021

Reposted by Anna Minchom

ALK Positive Lung Cancer UK @alkpositiveuk.bsky.social · 26/02/2025

ALK+ UK is off to @btog.bsky.social next week - a key event in #lungcancer - Debra Montague (Chair) & Geoff Otterman (Treasurer) are attending. We’re delighted to have 2 abstracts accepted for presentation. Looking forward to learning, connecting, & sharing patient perspectives. #BTOG25 #LCSM

193

Reposted by Anna Minchom

BTOG @btog.bsky.social · 11/02/2025

Delighted that our #BTOG25 Annual Conference keynote speaker is Pasi Jänne, translational thoracic medical oncologist at the Dana Farber Cancer Institute & professor of medicine at Harvard Medical School. Topic: “Novel strategies to targeting drug tolerant persistent state in lung cancer.” #LCSM

061

Reposted by Anna Minchom

Adam Sharp @asharpmedonc.bsky.social · 25/01/2025

@annaminchom.bsky.social and I will be doing a very slow jog on Tuesday am at ECMC JING meeting. Meet in foyer around 7am. Plenty of time for it to be a social jog, shower and breakie before we begin day 2. Can’t wait (for the meeting)!

132

Reposted by Anna Minchom

Udai Banerji @udaibanerji.bsky.social · 24/01/2025

www.icr.ac.uk/about-us/icr... Blog about projects @icrlondon.bsky.social in ovarian cancer. Its only the tip of the iceberg, there are many exciting projects too early to talk about! Blessed to be a small cog in the big wheel of progress in cancer research at my institution and beyond…

054

Reposted by Anna Minchom

Udai Banerji @udaibanerji.bsky.social · 08/01/2025

Very interesting personalized m-RNA cancer vaccine paper in nature medicine www.nature.com/articles/s41... published this week establishing proof concept of the technology. Trial was led by my colleague Juantia Lopez and our unit was involved as part of an international clinical trial.

nature.com

Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial - Nature Medicine

In this phase 1 trial, patients with locally advanced or metastatic solid tumors were treated with the individualized mRNA neoantigen-specific immunotherapy (iNeST) autogene cevumeran alone or in comb...

061

Reposted by Anna Minchom

Sanjay Popat @drsanjaypopat.bsky.social · 21/12/2024

Amazing to see recent NICE approvals: 1. Neoadjuvant alone (CM816): all PDL1 2. Perioperative (KN671, AGEAN) : all PDL1 3. Adjuvant (IMP010, TPS 50+; KN091 all PDL1) 4. Adjuvant EGFRm (ADAURA) 5. Adjuvant ALK+ (ALINA) Biomarker testing in early #NSCLC now critical!

1227